TIMP-1 expression in anaplastic large cell lymphoma is usually restricted to macrophages and only seldom observed in tumour cells

Journal of Pathology

Volumn 206, Issue 4, 2005, Pages 445-450

  Rust, Renata ^a   Blokzijl, Tjasso ^a   Harms, Geert ^a   Lim, Megan ^b   Visser, Lydia ^a   Kamps, Willem A ^a   Poppema, Sibrand ^a   van den Berg, Anke ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c NONE   (Netherlands)

Author keywords

ALCL; Macrophage; MMP 2; TIMP 1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; CD68 ANTIGEN; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 6; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MACROPHAGE; PRIORITY JOURNAL; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANTIGENS, CD; CELL LINE, TUMOR; CYTOKINES; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE-CELL; MACROPHAGES; MATRIX METALLOPROTEINASES; NEOPLASM PROTEINS; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANS-ACTIVATORS;

EID: 22644439354     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1796     Document Type: Article

References (26)

1. Stein H, Mason DY, Gerdes J, et al. The expression of Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cell. Blood 1985;66:848-858.
2. O'Connor NT, Stein H, Gatter KC, et al. Genotypic analysis of large cell lymphomas which express the Ki-1 antigen. Histopathology 1987;11:733-740.
3. Ohshima H, Kikuchi M, Masuda Y, et al. Genotypic and immunophenotypic analysis of anaplastic large cell lymphoma (Ki-1 lymphoma). Pathol Res Pract 1990;186:582-588.
4. Rimokh R, Magaud JP, Berger F, et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (Ki-1 lymphoma). Br J Haematol 1989;71:31-36.
5. Pittaluga S, Wlodarska I, Pulford K, et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 1997;151:343-351.
6. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56:379-390.
7. Chan WY, Liu QR, Borjigin J, et al. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry 1989;28:1033-1039.
8. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-1284.
9. Amin HM, McDonnell TJ, Ma Y, et al. Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004; 23:5426-5434.
10. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-954.
11. Lai R, Rassidakis GZ, Medeiros LJ, et al. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Am J Pathol 2004;164:2251-2258.
12. Henriet P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999;107:111-119.
13. Kruger A, Fata JE, Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 1997;90:1993-2000.
14. Wright JK, Cawston TE, Hazleman BL. Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim Biophys Acta 1991;1094:207-210.
15. Guedez L, Mansoor A, Birkedal-Hansen B, et al. Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis. Blood 2001; 97:1796-1802.
16. Kossakowska AE, Edwards DR, Prusinkiewicz C, et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999;94:2080-2089.
17. Gaiser T, Thorns C, Merz H, Noack F, Feller AC, Lange K. Gene profiling in anaplastic large-cell lymphoma-derived cell lines with cDNA expression arrays. J Hematother Stem Cell Res 2002; 11:423-428.
18. Thorns C, Feller AC, Merz H. EMMPRIN (CD 174) is expressed in Hodgkin's lymphoma and anaplastic large cell lymphoma: an immunohistochemical study of 60 cases. Anticancer Res 2002; 22:1983-1986.
19. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96:2304-2310.
20. Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004;172:567-576.
21. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4:197-250.
22. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 1996;73:1401-1408.
23. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996;7:147-154.
24. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 1999;5:711-720.
25. Vacca A, Moretti S, Ribatti D, et al. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 1997;33:1685-1692.
26. Delsol G, Ralfkiaer E, Stein H, Wright D, Jaffe ES. Anaplastic large cell lymphoma. In Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). IARC Press: Lyon, 2001; 230-235.